Why Are Indians in Their 30s Getting Hip Replacements? Corticosteroid-Induced Bone Necrosis After COVID-19

Avascular necrosis (AVN) of the femoral head is defined as the death of bone tissue in the rounded top of the thighbone caused by a disrupted blood supply — and post-COVID India is now confronting it at a scale that has genuinely unsettled the orthopaedic community. Hospitals across the country are reporting a 40% rise in total hip replacement surgeries among patients in their 30s and 40s, a demographic that, until the pandemic, had little reason to be in an orthopaedic ward at all. The figure was shared at a major national orthopaedic conference in mid-2026 and reflects a trend that has been building quietly since 2022.

During India's catastrophic second wave, high-dose corticosteroids — primarily dexamethasone and methylprednisolone — were administered widely to prevent cytokine storm and respiratory failure. They worked. But for a portion of those patients, the treatment left behind a slower, less visible injury: the gradual collapse of the femoral head, starved of blood, progressing silently for months or years before pain forced a clinical visit.

At a Glance: Corticosteroid-Induced AVN vs. Other Common Causes

Feature	Corticosteroid-Induced AVN (Post-COVID)	Alcohol-Related AVN	Trauma-Related AVN
Typical age at diagnosis	30s–40s	40s–50s	Any age, post-injury
Primary mechanism	Steroid-driven fat embolism + impaired lipid metabolism disrupting femoral head blood supply	Fatty liver → lipid emboli in bone vasculature	Direct disruption of blood vessels at fracture site
Onset after trigger	6 months – 3 years post steroid exposure	Years of heavy use	Weeks to months post-fracture
Bilateral involvement	Common (both hips affected in many cases)	Less common	Rare (usually unilateral)
Early detection tool	MRI (detects changes before X-ray)	MRI	X-ray + MRI
Reversible if caught early?	Yes — core decompression possible in Stage I–II	Yes, if caught early	Depends on severity
Endpoint without treatment	Total hip replacement	Total hip replacement	Total hip replacement
India-specific surge post-2021	Yes — documented 40% rise in 30s–40s age group	No documented surge	No documented surge

What distinguishes the post-COVID cohort is not the disease mechanism — steroids causing AVN has been documented since the SARS-CoV-1 outbreak of 2003 — but the sheer scale and the youth of the affected population.

What Exactly Is Avascular Necrosis of the Femoral Head?

Avascular necrosis of the femoral head is a progressive pathological condition in which the blood supply to the rounded head of the femur is interrupted, causing bone cells to die and the structural integrity of the joint to deteriorate. Without adequate blood flow, the bone cannot repair itself, and the femoral head — which bears the entire weight of the body during standing and walking — begins to flatten and collapse inward.

The femoral head is particularly vulnerable to vascular disruption because it is supplied by a limited network of end arteries with few collateral pathways. When those arteries are compromised — whether by fat emboli, increased intraosseous pressure, or direct vascular injury — the bone has almost no backup circulation to draw on.

Research published in the Annals of Medicine and Surgery documented cases of bilateral hip AVN in patients as young as 27 years old following COVID-19 treatment with corticosteroids and antivirals, with no prior comorbidities. The authors concluded that "viral invasion combined with irrational steroid use is the driving force behind the occurrence of AVN in COVID-19 patients." The cases were diagnosed through MRI after patients presented with bilateral hip pain — a presentation that, in a 27-year-old, would previously have been almost unthinkable.

How Do Corticosteroids Damage Bone?

The link between corticosteroids and AVN has been established for decades, but the COVID-19 pandemic created a unique convergence of factors that amplified the risk dramatically.

Corticosteroids damage bone vasculature through several overlapping mechanisms. First, they promote fat cell differentiation in bone marrow, increasing intraosseous fat deposits and raising pressure inside the rigid bone cavity. This elevated pressure compresses the small blood vessels that feed the femoral head, reducing perfusion. Second, steroids impair lipid metabolism systemically, promoting hyperlipidaemia and increasing the risk of fat emboli circulating to the bone's microvasculature. Third, they suppress osteoblast activity — the cells responsible for building new bone — while simultaneously promoting osteoclast activity, which breaks bone down. The net result is a bone that is simultaneously losing structural mass and losing its blood supply.

A full review published in PMC examining COVID-19-related steroid-induced AVN found that the risk is strongly dose- and duration-dependent. Cumulative doses exceeding 2,000 mg of prednisolone equivalent are associated with significantly higher AVN incidence. During India's second wave, many patients received high-dose methylprednisolone pulse therapy — sometimes 500–1,000 mg per day for three to five days — in addition to prolonged oral dexamethasone. For patients who received multiple courses or extended regimens, cumulative doses easily crossed the threshold associated with bone necrosis.

The COVID-19 virus itself may also contribute independently of steroids. SARS-CoV-2 has been shown to cause endothelial dysfunction and a hypercoagulable state — both of which can impair blood flow to the femoral head even without steroid exposure. Some patients may have developed AVN from the infection alone, though the steroid-exposed cohort represents the bulk of documented cases.

Why Did India's Second Wave Create Such a Large At-Risk Population?

India's second wave, which peaked in May 2021, was catastrophic in its speed and severity. Hospitals were overwhelmed, oxygen supplies ran critically short, and clinicians — facing a rapidly deteriorating patient population — turned to corticosteroids as one of the few interventions with proven mortality benefit in severe COVID-19. The WHO had endorsed dexamethasone for severe cases based on the UK's RECOVERY trial, but the protocol was often applied more broadly in India's overwhelmed healthcare settings, including in moderate cases where the benefit-risk calculation was less clear.

According to The Hindu, the patients now presenting with AVN are not people who took unnecessary risks. They were treated, they recovered, and they returned to their lives — as software engineers, teachers, and daily-wage workers. The steroid use that saved their lungs was clinically justified at the time. The bone damage that followed was an unintended consequence of a medical emergency, not a failure of individual decision-making.

The scale of India's second wave means the at-risk population is large. Tens of millions of Indians were infected during that period, and a significant fraction received corticosteroids. Even if only a small percentage develop AVN, the absolute numbers are substantial — and the five-year lag between steroid exposure and clinical presentation means the wave of diagnoses is still building.

What Are the Early Warning Signs, and Why Are They So Easy to Miss?

The tragedy of AVN is partly a tragedy of symptom ambiguity. The early warning signs — a dull ache in the groin, mild stiffness after prolonged sitting, a barely noticeable limp — are indistinguishable from the kinds of musculoskeletal complaints that any desk-bound professional in their 30s might attribute to poor posture, a gym strain, or a long commute.

Orthopaedic specialists quoted in The Hindu note that most patients dismiss these early symptoms for months, hoping the pain will resolve on its own. By the time the pain becomes impossible to ignore — typically when the femoral head has partially collapsed and every step generates significant discomfort — the window for joint-preserving intervention has often closed.

This delay matters enormously because AVN is staged, and treatment options differ dramatically by stage:

Stage I — Bone changes visible only on MRI; no collapse. Core decompression (drilling small channels to relieve intraosseous pressure and stimulate new blood vessel growth) can halt progression and preserve the joint in a significant proportion of patients.

Stage II — Sclerosis and cysts visible on X-ray, but femoral head shape intact. Core decompression with or without bone grafting remains an option.

Stage III — Crescent sign on X-ray indicating subchondral fracture; femoral head beginning to flatten. Joint-preserving surgery becomes technically difficult; outcomes are less predictable.

Stage IV — Femoral head collapse with secondary osteoarthritis of the acetabulum. Total hip replacement is typically the only viable option.

The majority of post-COVID AVN patients in India are presenting at Stage III or IV, according to clinicians at the national orthopaedic conference cited in The Hindu. This is not because early-stage AVN is undetectable — MRI can identify bone marrow oedema and early necrotic changes before any collapse occurs — but because awareness is low and access to MRI for what initially presents as vague hip discomfort is limited in much of India.

Who Is Most at Risk Among COVID-19 Survivors?

Not every COVID-19 patient who received corticosteroids will develop AVN. The condition appears to cluster in patients who received higher cumulative steroid doses, those who received multiple courses, and those with certain underlying metabolic risk factors. The highest-risk profile includes:

Patients who received pulse methylprednisolone therapy (500 mg or more per day) during hospitalisation, particularly if followed by a prolonged oral taper. Patients who received steroids for more than three weeks in total. Patients with pre-existing hyperlipidaemia, diabetes, or obesity — conditions that independently impair bone vasculature and were common in India's severe COVID-19 cohort. Patients who were treated during the second wave (April–June 2021) when steroid protocols were least standardised and most aggressively applied.

The case report published in Annals of Medicine and Surgery is instructive: both patients — aged 27 and 69 — had no prior comorbidities, yet developed bilateral AVN following COVID-19 treatment. This suggests that even in metabolically healthy individuals, the combination of SARS-CoV-2 infection and corticosteroid exposure can be sufficient to trigger the condition.

Bilateral involvement — both hips affected simultaneously — is a particularly notable feature of steroid-induced AVN and distinguishes it from trauma-related AVN, which is almost always unilateral. When a patient in their 30s presents with pain in both hips, the index of suspicion for steroid-induced AVN should be high.

How Is AVN Diagnosed, and What Does the Diagnostic Pathway Look Like?

Diagnosis of AVN is confirmed through a combination of patient history, physical examination, and imaging that establishes bone death in the femoral head.

The key diagnostic principle is that standard X-rays are inadequate for early detection. X-rays can only detect AVN once structural changes — flattening, collapse, or sclerosis — are already visible, which corresponds to Stage II or later. By that point, the opportunity for joint preservation is significantly reduced.

MRI is the gold standard for early AVN detection. It can identify the characteristic "double-line sign" — a band of low signal intensity on T1-weighted images surrounded by a rim of high signal on T2 — which represents the interface between necrotic and viable bone, often before any symptoms are present. For any COVID-19 survivor who received high-dose steroids and is now experiencing groin pain or hip stiffness, an MRI of both hips (not just the symptomatic one) is the appropriate first investigation.

As noted by The Hindu, awareness of this diagnostic pathway remains low among both patients and primary care physicians. Many patients are initially managed with physiotherapy or anti-inflammatory medications — treatments that address the symptom but not the underlying pathology — losing critical weeks or months in the process.

What Are the Treatment Options?

Treatment of AVN depends entirely on stage at diagnosis, which is why early detection is so consequential.

Core decompression is the most widely used joint-preserving procedure for early-stage AVN. It involves drilling one or more channels from the outer cortex of the femur into the necrotic zone, reducing intraosseous pressure and creating a pathway for new blood vessel ingrowth. Success rates are highest in Stage I (up to 80% joint preservation at five years in some series) and decline significantly with advancing stage. Core decompression can be combined with bone grafting — either autologous cancellous bone or vascularised fibular grafts — to provide structural support and additional biological stimulus for healing.

Bisphosphonates have been studied as a pharmacological adjunct to slow AVN progression by inhibiting osteoclast activity and reducing bone resorption. Evidence is mixed; some trials show modest benefit in early-stage disease, but bisphosphonates cannot reverse established necrosis or restore blood supply.

Total hip replacement (THR) is the definitive treatment for advanced AVN (Stage III–IV) and involves replacing the damaged femoral head and acetabular socket with prosthetic components. In older patients, THR outcomes are excellent and durable. In patients in their 30s, the picture is more complicated: prosthetic implants have a finite lifespan (typically 15–25 years for modern implants), meaning a 35-year-old undergoing THR today will almost certainly require at least one revision surgery in their lifetime. Revision hip replacement is technically more demanding, carries higher complication rates, and is associated with worse functional outcomes than primary replacement.

This is why the surge in THR among young Indians is not just a statistic — it represents a long-term healthcare burden that will compound over the coming decades as this cohort ages and their implants wear out.

What Should India's Healthcare System Do Differently?

Dr Sai Krishna B. Naidu, lead consultant for joint replacement and sports injuries at Manipal Hospital Yelahanka and Hebbal, writing in The Hindu, argues that India's healthcare system now faces an uncomfortable reckoning. The generation that bore the heaviest economic burden of the pandemic is now facing its physical cost. What is owed to them, at minimum, is faster diagnosis, wider screening access, and a medical system that takes post-COVID bone disease as seriously as it does the more visible long-COVID symptoms — breathlessness, fatigue, brain fog.

Several concrete changes would make a measurable difference:

Targeted screening programmes for COVID-19 survivors who received high-dose steroids. A registry-based approach — identifying patients from hospital records of second-wave admissions who received pulse steroids — would allow proactive outreach and MRI screening before symptoms develop. This is technically feasible; the barrier is institutional will and funding.

Primary care education so that general practitioners and family physicians recognise groin pain and hip stiffness in a post-COVID patient in their 30s as a red flag warranting MRI, not just physiotherapy. The diagnostic delay is partly a knowledge gap at the primary care level.

Rationalised steroid protocols going forward. The PMC review and the Annals of Medicine and Surgery case report both emphasise that the lowest effective dose for the shortest effective duration remains the key to minimising AVN risk. This principle was not always followed during the chaos of India's second wave, but it must be embedded in future pandemic preparedness protocols.

Subsidised MRI access for post-COVID bone disease screening. MRI remains expensive relative to median incomes in India, and the patients most at risk — daily-wage workers, informal sector employees — are least able to afford it out of pocket. A targeted public health subsidy for this specific indication would be cost-effective given the downstream cost of total hip replacement and revision surgery.

What Does This Mean for COVID-19 Survivors Right Now?

For the millions of Indians who were hospitalised during the second wave and received corticosteroids, the practical message is straightforward: if you have experienced any groin pain, hip stiffness, or a subtle change in your gait since recovering from COVID-19, do not wait. Request an MRI of both hips. Do not accept a diagnosis of "muscle strain" or "desk-job posture" without imaging confirmation.

The window for joint-preserving treatment is real but finite. Core decompression performed in Stage I or early Stage II can preserve the hip joint and avoid the need for replacement surgery. That window closes as the femoral head collapses. The difference between catching AVN at Stage I and Stage IV is the difference between a day-surgery procedure and a total joint replacement that will need to be revised in 20 years.

The Annals of Medicine and Surgery authors are explicit: "Early detection of Avascular necrosis is very crucial in its management due to its high progression rate." The progression from early to late-stage AVN can occur within months in some patients. Waiting to see if the pain resolves is not a neutral choice — it is a choice that may foreclose treatment options.

The Broader Context: Long COVID and Bone Health

AVN is one of several musculoskeletal consequences now being attributed to COVID-19 and its treatment. Post-COVID bone health is an emerging field, and the full spectrum of long-term skeletal consequences is not yet characterised. What is clear is that the virus and its treatment have effects that extend well beyond the respiratory system.

The PMC full review situates corticosteroid-induced AVN within the broader category of long-COVID complications — conditions that persist or emerge after the acute infection has resolved. This framing matters for public health policy: long COVID has received significant research funding and clinical attention in Western countries, but the bone-specific complications have received comparatively little focus, particularly in the Indian context where steroid use during the second wave was especially widespread.

India's experience with post-COVID AVN is also a cautionary tale for future pandemic preparedness. The SARS-CoV-1 outbreak of 2003 produced a similar wave of steroid-induced AVN in affected patients — a pattern that was documented in the medical literature but apparently not sufficiently integrated into COVID-19 treatment protocols when the pandemic began. The lesson for the next outbreak is that any corticosteroid protocol deployed at scale must be accompanied by active surveillance for AVN and a clear plan for screening survivors.

The hips of a 35-year-old should not tell the story of a pandemic. In India in 2026, increasingly, they do — and the medical system's response to that reality will define whether this generation receives the care it is owed, or whether the physical cost of COVID-19 compounds quietly for decades to come.

For related reading on bone and metabolic health in India, see our evidence-based guides on berberine for insulin resistance and blood sugar control and best magnesium glycinate capsules in India, both of which address metabolic risk factors relevant to bone vascular health.